glp 1 and pancreatitis GLP-1 Agonists Risk glp-1 pancreatitis law firm in
Description
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1RA) in high-risk patients with type 2 diabetes
This regulatory vacuum underscores the urgency for coordinated efforts to adapt imaging protocols worldwide
Schenker, N
Front Endocrinol 13:945609
This can then create false signals where a medication appears to have a higher risk because of increased reporting, not actual incidence
January 22, 2024
